Dashboard/CAPLIPOINT

CAPLIPOINT

FAIRLY_VALUED

Caplin Point Laboratories

Pharma · NSE

↑ 6.2% vs fair value

52W Low

₹1,500

+4.7% from low

52W High

₹2,395

-34.4% from high

News sentiment (1 articles)

1 bull0 neutral0 bear

✦

Analyst Note

2d ago

Caplin Point Laboratories trades fairly valued at ₹1,571, sitting 6.2% below its fair value of ₹1,675 with medium confidence. The pharma company demonstrates solid fundamentals with 18.3% earnings growth over the past year and strong free cash flow of ₹241 Cr, supported by a pristine zero debt balance and high-quality cash-backed earnings (Piotroski score of 8). However, ROCE is deteriorating at 23.3%, and the stock trades below its 50-day and 200-day moving averages despite consistent bullish sentiment. This suits value-conscious investors comfortable with modest upside and a defensive portfolio anchor in pharmaceuticals.

Valuation Gauge

FAIRLY_VALUED+6.2% Margin of Safety

OVERVALUEDFAIRLY VALUEDUNDERVALUED

Current Price

₹1,571

Fair Value

₹1,675

Fair Value Analysis

₹1,675

Based on free cash flow projections and earnings growth potential for Pharma sector companies | Sector-cheap: P/E at 20th percentile vs sector peers. | CAUTION: ROCE declining (latest 22.8%) — returns on capital are falling; verify this isn't a value trap.

Medium confidence

Cash Flow Analysis

38% weight

₹350

Growth Valuation

63% weight

₹2,471

Price vs Market

CAPLIPOINT

Nifty 50

Shareholding Pattern

Stock Health Score

Financially Strong

8.6 / 10

Profitability

10/10

ROE of 19.7% is above the Pharma sector benchmark of 18% — strong returns

Debt & Leverage

10/10

D/E ratio of 0.0x is well within the Pharma sector norm of 0.8x — strong balance sheet

Valuation vs Peers

10/10

P/E of 19.5x trades at a 54% discount to Pharma sector median (42x) — attractively valued

Cash Flow

8/10

FCF margin of 12.4% — strong cash generation (₹241 Cr)

Earnings Growth

8/10

5yr EPS CAGR of 21.4% is in line with the Pharma sector average of 15.3%

Dividend

4/10

Dividend yield of 0.4% is symbolic — low but positive

Sentiment Trend — Last 30 Days

Historical Returns

Key Ratios & Growth

FCF Yield

0.8%

Free cash flow / market cap

Revenue Growth (YoY)

+10.1%

Year-on-year revenue change

Profit Growth (YoY)

+18.6%

Year-on-year PAT change

Operating Cash Flow

₹432 Cr

TTM cash from operations

Key Financials

EPS (TTM)

₹80.7

P/E Ratio

19.5x

P/B Ratio

3.8x

ROE

19.7%

ROCE

23.3%

Debt / Equity

Beta

0.11

Div Yield

0.4%

FCF (Cr)

₹241 Cr

Revenue (Cr)

₹1,937 Cr

EPS Growth 5Y

21.4%

Mkt Cap (Cr)

₹11,922 Cr

52W High

₹2,395

52W Low

₹1,500.3

Book Value/Share

₹410.3

Financial History

Period	Revenue	Op Profit	OPM%	PAT	EPS
TTM	₹2.1K Cr	₹725 Cr	35.0%	₹622 Cr	₹80.74
2025-03-31	₹1.9K Cr	₹651 Cr	34.0%	₹541 Cr	₹70.56
2024-03-31	₹1.7K Cr	₹552 Cr	33.0%	₹461 Cr	₹60.19
2023-03-31	₹1.5K Cr	₹442 Cr	30.0%	₹377 Cr	₹49.57
2022-03-31	₹1.3K Cr	₹395 Cr	31.0%	₹308 Cr	₹39.56
2021-03-31	₹1.1K Cr	₹329 Cr	31.0%	₹251 Cr	₹32.03
2020-03-31	₹863 Cr	₹260 Cr	30.0%	₹215 Cr	₹28.42
2019-03-31	₹649 Cr	₹232 Cr	36.0%	₹177 Cr	₹23.35
2018-03-31	₹540 Cr	₹195 Cr	36.0%	₹145 Cr	₹19.15
2017-03-31	₹402 Cr	₹125 Cr	31.0%	₹96 Cr	₹12.65
2016-03-31	₹239 Cr	₹64 Cr	27.0%	₹46 Cr	₹6.05
2015-06-30	₹252 Cr	₹60 Cr	24.0%	₹41 Cr	₹5.43
2014-06-30	₹173 Cr	₹36 Cr	21.0%	₹26 Cr	₹3.42

Compounded Growth Rates

Sales Growth

3Y+12.5%

5Y+14.5%

10Y+24.2%

Profit Growth

3Y+18.2%

5Y+19.9%

10Y+29.7%

EPS Growth

3Y+17.7%

5Y+20.3%

10Y+29.6%

Peer Comparison

Pharma

Stock	Price	Fair Value	MoS%	P/E	ROE	Signal
PAR Par Drugs And Chemicals Limited	₹86	₹469.7	+81.7%	7.3	15.4%	FAIRLY_VALUED
IOLCP IOL Chemicals and Pharmaceuticals Limited	₹79.5	₹237.8	+66.6%	19.6	5.2%	FAIRLY_VALUED
KILITCH Kilitch Drugs (India) Limited	₹132.7	₹321	+58.7%	17.7	9.4%	UNDERVALUED
BALPHARMA Bal Pharma Limited	₹69	₹147.5	+53.2%	12.8	12.6%	FAIRLY_VALUED
ZYDUSLIFE Zydus Lifesciences	₹868	₹1,502.2	+42.2%	17.6	19.9%	UNDERVALUED
NATCOPHARM Natco Pharma	₹1,030	₹1,597	+35.5%	11.8	18.0%	UNDERVALUED
JAGSNPHARM Jagsonpal Pharmaceuticals Limited	₹190.6	₹275.2	+30.7%	30.8	20.1%	UNDERVALUED
LUPIN Lupin	₹2,280	₹3,112	+26.7%	22.4	23.8%	UNDERVALUED